» Articles » PMID: 34170974

North Star Ambulatory Assessment Changes in Ambulant Duchenne Boys Amenable to Skip Exons 44, 45, 51, and 53: A 3 Year Follow Up

Abstract

Introduction: The aim of this study was to report 36-month longitudinal changes using the North Star Ambulatory Assessment (NSAA) in ambulant patients affected by Duchenne muscular dystrophy amenable to skip exons 44, 45, 51 or 53.

Materials And Methods: We included 101 patients, 34 had deletions amenable to skip exon 44, 25 exon 45, 19 exon 51, and 28 exon 53, not recruited in any ongoing clinical trials. Five patients were counted to skip exon 51 and 53 since they had a single deletion of exon 52.

Results: The difference between subgroups (skip 44, 45, 51 and 53) was significant at 12 (p = 0.043), 24 (p = 0.005) and 36 months (p≤0.001).

Discussion: Mutations amenable to skip exons 53 and 51 had lower baseline values and more negative changes than the other subgroups while those amenable to skip exon 44 had higher scores both at baseline and at follow up.

Conclusion: Our results confirm different progression of disease in subgroups of patients with deletions amenable to skip different exons. This information is relevant as current long term clinical trials are using the NSAA in these subgroups of mutations.

Citing Articles

The complex landscape of DMD mutations: moving towards personalized medicine.

Gatto F, Benemei S, Piluso G, Bello L Front Genet. 2024; 15:1360224.

PMID: 38596212 PMC: 11002111. DOI: 10.3389/fgene.2024.1360224.


Population longitudinal analysis of Gait Profile Score and North Star Ambulatory Assessment in children with Duchenne muscular dystrophy.

Deng J, Liu F, Feng Z, Liu Z CPT Pharmacometrics Syst Pharmacol. 2024; 13(5):891-903.

PMID: 38539027 PMC: 11098163. DOI: 10.1002/psp4.13126.


Detecting early signs in Duchenne muscular dystrophy: comprehensive review and diagnostic implications.

Mercuri E, Pane M, Cicala G, Brogna C, Ciafaloni E Front Pediatr. 2023; 11:1276144.

PMID: 38027286 PMC: 10667703. DOI: 10.3389/fped.2023.1276144.


Quantifying Variability in Motor Function in Duchenne Muscular Dystrophy: UK Centiles for the NorthStar Ambulatory Assessment, 10 m Walk Run Velocity and Rise from Floor Velocity in GC Treated Boys.

Stimpson G, Ridout D, Wolfe A, Milev E, OReilly E, Manzur A J Neuromuscul Dis. 2023; 11(1):153-166.

PMID: 37980680 PMC: 10789350. DOI: 10.3233/JND-230159.


Upper Limb Changes in DMD Patients Amenable to Skipping Exons 44, 45, 51 and 53: A 24-Month Study.

Brogna C, Pane M, Coratti G, DAmico A, Pegoraro E, Bello L Children (Basel). 2023; 10(4).

PMID: 37189996 PMC: 10136754. DOI: 10.3390/children10040746.


References
1.
Alfano L, Charleston J, Connolly A, Cripe L, Donoghue C, Dracker R . Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy. Medicine (Baltimore). 2019; 98(26):e15858. PMC: 6617421. DOI: 10.1097/MD.0000000000015858. View

2.
Mazzone E, Pane M, Sormani M, Scalise R, Berardinelli A, Messina S . 24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy. PLoS One. 2013; 8(1):e52512. PMC: 3543414. DOI: 10.1371/journal.pone.0052512. View

3.
Van Vliet L, de Winter C, van Deutekom J, van Ommen G, Aartsma-Rus A . Assessment of the feasibility of exon 45-55 multiexon skipping for Duchenne muscular dystrophy. BMC Med Genet. 2008; 9:105. PMC: 2611974. DOI: 10.1186/1471-2350-9-105. View

4.
Brogna C, Coratti G, Pane M, Ricotti V, Messina S, DAmico A . Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53. PLoS One. 2019; 14(6):e0218683. PMC: 6592545. DOI: 10.1371/journal.pone.0218683. View

5.
Servais L, Montus M, Le Guiner C, Ben Yaou R, Annoussamy M, Moraux A . Non-Ambulant Duchenne Patients Theoretically Treatable by Exon 53 Skipping have Severe Phenotype. J Neuromuscul Dis. 2016; 2(3):269-279. PMC: 5240539. DOI: 10.3233/JND-150100. View